242Users Online
羅依sacea Treatment Market Segmented By Antimicrobials, Alpha agonists, Retinoid Drugs in Institutional Sales, and Retail sales
Theglobal rosacea therapeutics marketreached a valuation ofUS$3.94 Bnin 2021. Demand for rosacea therapeutic delivery systems and drugs is predicted to expand at a CAGR of6.2%to reachUS$ 7.61 Bnby the year 2032.
羅依sacea Therapeutics Market Size (2021) |
US$ 3.94 Bn |
Projected Market Value (2032) |
US$ 7.61 Bn |
Global Market Growth Rate (2022-2032) |
6.2% CAGR |
Market Share of Top 5 Countries |
59% |
As per detailed industry analysis by Persistence Market Research, oral antibiotics are expected to drive high market growth after holding a market share of29.3%in 2021. Rosacea therapeutics accounted for a share of10%in the global dermatology drugs market in 2021.
Free Report Sample is Available!
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
The global rosacea treatment drugs market expanded at a CAGR of5.6%over the last five years (2017-2021).
As indicated by the Centres for Disease Control and Prevention and as per 2021 OECD Health Statistics, per capita medical services spending increase by around 4.9% in 2020. This was essentially driven by state-run administrations distributing more conspicuous resources for prosperity, including creating medical care framework.
With the rising need for novel healthcare products and regulations that came into the picture, demand for rosacea therapeutic drugs delivery systems is expected to steadily rise over the coming years.
羅依sacea is a typical skin condition portrayed by redness and apparent veins on the face. The nose and cheeks are the most impacted parts. The signs and side effects of rosacea are little, red, discharge-filled knocks that erupt intermittently. A large portion of patients experience eye dryness and blushed eyelids. Other side effects include augmented nose and thickening of the skin around the nose (rhinophyma).
包括辛辣食物和ho Rosacea-trigger因素t drinks, alcohol, extreme differences in temperature, exercise, cosmetics, drugs that dilate blood vessels, including some blood pressure medications, and others. There has been rising exposure to these triggers owing to increased urbanization and industrialization. Rising use of cosmetics and a hypertensive population also drive rosacea incidence.
The global rosacea therapeutic drug delivery systems market is expected to expand at a CAGR of6.2%and record sales worthUS$7.61Bnby the end of 2032.
Make This Report Your Own!
Take Advantage of Intelligence Tailored to your Business Objective
Request A Customized Version“Need for More Effective Drugs for Rosacea Treatment”
With the growing rate of product adoption, the untapped rosacea therapeutics market will offer numerous beneficial opportunities for key players.
Available drug treatment options fulfill a short-term, palliative role, and are rarely used alone as a long-term therapy. Currently, antibiotics such as doxycycline and topical metronidazole or azelaic acid are the first-line agents in the treatment of rosacea. None of the available rosacea treatment drugs target the cause of the disease. Thus, there is an unmet medical need for more effective drugs targeting the root cause of the disease.
The research and development pipeline of rosacea therapeutics is comparatively weak as compared to other diseases. Thus, a large gap exists between demand and the current therapies.
The NRS (National Rosacea Society's) research awards program has granted more than US$ 1.6 Mn to help 75 examinations, including logical examinations that have drawn an obvious conclusion in the provocative cycle, a critical hidden factor in the confusion. This commencement can attract many researchers and scientists in developing new medicines for rosacea treatment.
Growing research & development expenditure by companies is one of the major market opportunities owing to technological gains and the shorter time and resources needed to market products owing to low elasticity of demand. Low treatment rates of rosacea present another major market opportunity.
“Non-life-threatening Nature of Rosacea & Poor Efficacy of Treatment Options”
羅依sacea is generally not life-threatening, although cutaneous dissemination may occur, which results in high elasticity of demand. Treatment rates of rosacea are low, as most individuals suffering from rosacea use nothing at all for the condition or are notoriously non-adherent, probably because they consider the treatment ineffective.
Lack of effective diagnostic tests is another restraint for the rosacea treatment products market, resulting in false negatives.
Poor efficacy of treatment and the non-life-threatening nature of rosacea has resulted in large competition from alternative treatments, which are often not effective. Rosacea patients use a large assortment of non-prescription skincare products, including mild cleansers, moisturizers, and sunscreens, which drives down the market for rosacea therapeutics.
Side-effects associated with the usage of antibiotics can also lead to gastric discomfort, which includes nausea, gastritis, bloating and indigestion, loss of appetite, and abdominal pain.
Why is the U.S. a Prominent Market for Rosacea Therapeutics?
“High Awareness about Rosacea and its Treatment”
In 2021, the U.S. dominated the North America rosacea therapeutics market with over91%market share. In the U.S. there is a high level of awareness among patients as well as end users about rosacea and its several treatment options, which has significantly driven the uptake of rosacea therapeutic products in the country.
Additionally, according to the Centres for Disease Control and Prevention, almost 16 Mn people in the U.S. suffer from rosacea. Thus, increase in prevalence of rosacea is also one of the major reasons of driving demand for rosacea therapeutics in the U.S. market.
How is Demand for Rosacea Treatment Shaping Up in Germany?
“Huge Healthcare Expenditure Coupled with High Rate of Diagnosis & Treatment”
In terms of value share, Germany accounts for36.9%of the Europe rosacea therapeutics market. High rate of treatment and diagnosis coupled with huge healthcare expenditure and various collaborations drive the Germany market.
Furthermore, quality health services, growing aging population, and rising skin diseases are estimated propel demand growth of rosacea treatment products in Germany.
Will the Emerging Market of China Provide Lucrative Opportunities for Rosacea Treatment Providers?
“Rapidly Rising Incidence of Rosacea in China”
The China rosacea therapeutics market accounts for more than 50% of the East Asian market share. In 2021, the market in China was valued atUS$ 350.4 Mn.
According to the Indian Journal of Dermatology, Venereology, and Leprology 2020, incidence of rosacea is rising in China, which is one of the most prominent factor boosting market growth in the country.
Which Type of Disease is Most Commonly Catered to in Rosacea Therapeutics?
“Erythematotelangiectatic Rosacea Most Commonly Occurring Disease Type”
Erythematotelangiectatic rosacea, a subtype of rosacea that is characterized by recurrent episodes of transient face erythema (flushing) and no transient, or chronic erythema, is most common.
This segment held the highest market share of around35.4%in the year 2021, and is expected to expand at a CAGR of6.8%over the forecast period (2022-2032).
Which Drug Class is Most Popular in this Market Space?
“Antibiotics - Most Preferred Rosacea Treatment Option”
Antibiotics drug class is the leading segment in this market, and is set to account for a market share of39.5%and expand at a CAGR of6.4%over the forecast period (2022-2032).
Antibiotics are the most commonly preferred drug class by physicians and doctors for early relief from the disease. The high demand for antibiotics in the treatment of rosacea is the main factor that leads to account for the highest market share.
Which Distribution Channel Will Benefit Market Players the Most?
“Retail Sales of Rosacea Treatment Drugs the Highest”
The retail sales segment accounted for52.1%market share, by value, in 2021, and is expected to expand at a CAGR of6.4%during the forecast period.
幾乎所有的抗生素和維生素e的高可用性asy access to these stores make this segment the most lucrative one as compared to others.
With the onset of COVID-19, one of the most important elements affecting the rosacea treatment drugs’ supply chain and price increase was geographic location. Extended use of face masks increased the indications and symptoms of rosacea, which was the most prominent effect of the pandemic on the prevalence of rosacea. Excessive face mask use has been linked to an increase in the occurrence of symptoms in papulopustular and erythematotelangiectatic rosacea.
Companies are strategically focusing on enhancing the distribution of their products in high profit-making markets. Key market players are promoting their products at professional scientific meetings and conferences.
Additionally, key players are actively focusing on partnerships and collaborating with suppliers to have a strong position and also to expand access to rosacea treatment drugs for patients.
Attribute |
Details |
Forecast Period |
2022-2032 |
Historical Data Available for |
2017-2021 |
Market Analysis |
US$ Million for Value |
Key Countries Covered |
|
Key Market Segments Covered |
|
Key Companies Profiled |
|
Report Coverage |
|
Customization & Pricing |
Available upon Request |
羅依sacea Therapeutics Market by Disease Type:
羅依sacea Therapeutics Market by Drug Class:
通過治療紅斑痤瘡治療市場類型:
羅依sacea Therapeutics Market by Route of Administration:
羅依sacea Therapeutics Market by Distribution Channel:
羅依sacea Therapeutics Market by Region:
The global rosacea therapeutics market is currently valued atUS$ 3.94 Bn, and is expected to grow1.9Xby 2032.
The rosacea therapeutics industry is set to witness a high growth rate of6.2%over the forecast period and reachUS$ 7.61 Bnby 2032.
Consumption of rosacea treatment drugs increased at the rate of5.6%from 2017 to 2021.
Galderma, AbbVie, Inc., Pfizer Inc., Sanofi SA, Janssen Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd are key players manufacturing rosacea therapeutic drugs.
The U.S., China, Germany, Brazil, and Japan currently hold more than50%global market share.
The North America market for rosacea therapeutics market is one of the fastest-growing markets globally, and accounted forUS$ 1.28 Bnin 2021.
The Europe rosacea treatment market worth is expected to record a CAGR of6.9%over the forecast period.
The China market held a share of54.6%in East Asia in 2021, with Japan accounting for28.3%market share.
